Immunome (Immunome) 5-Year EBITDA Growth Rate : -0.30% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Immunome 5-Year EBITDA Growth Rate?

Immunome's EBITDA per Share for the three months ended in Dec. 2023 was $-0.31.

During the past 3 years, the average EBITDA Per Share Growth Rate was 34.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Immunome was 34.50% per year. The lowest was -20.90% per year. And the median was -9.00% per year.

Competitive Comparison of Immunome's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Immunome's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunome's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunome's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Immunome's 5-Year EBITDA Growth Rate falls into.

Immunome 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Immunome (NAS:IMNM) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Immunome 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Immunome's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunome (Immunome) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunome Inc (NAS:IMNM) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

665 Stockton Drive, Suite 300, Exton, PA, USA, 19341

Website

https://www.immunome.com

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. It primarily operates in the U.S. Its current programs comprise Oncology (IMM-ONC-01), SARS-CoV-2 (IMM-BCP-01), and IMM20059 Anti-EPN1.

Executives

Jean Jacques Bienaime	director	925 PAGE MILL ROAD, PALO ALTO CA 94304
Robert Lechleider	officer: Chief Medical Officer	C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300 PA 19341
Max Rosett	officer: SVP Operations	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Clay B Siegall	director, officer: President and CEO	21823 30TH DR SE, BOTHELL WA 98021
Jack Higgins	officer: Chief Scientific Officer	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Isaac Barchas	director, other: See remarks	1601 BRYAN STREET, SUITE 4141, DALLAS TX 75201
Bruce Turner	officer: Chief Strategy Officer	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
James P Boylan	director	C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Matthew K Robinson	officer: Chief Technology Officer	C/O IMMUNOME, INC., 665 STOCKTON DRIVE SUITE 300, EXTON PA 19341
Michael Rapp	director, 10 percent owner	712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Franklyn G Prendergast	director
Michael Lefenfeld	director	IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
Purnanand D Sarma	director, officer: President and CEO	IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
John L Lamattina	director	81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Philip Wagenheim	director	712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019